For VA Providers: SAVI Dual is now a covered VA benefit

Veterans may be more likely to experience migraine attacks and headaches than civilians.

In 2018, Congress mandated that the VA establish the Headache Centers of Excellence (HCOE) to address the growing need for improved care within the VA Healthcare System.  The care of migraine has now expanded through the VA using the care guidelines established by the HCOE.

The use of non-medication neuromodulation is included in those care guidelines and is a covered VA benefit.

SAVI Dual is the only non-invasive, patient-administered central neuromodulation device that directly targets and signals the brain to quiet the hyperactive nerves thought to be the source of migraine.  This smart technology includes Remote Therapeutic Monitoring that allows you to monitor patient progress.

Contact Us

How to Prescribe SAVI Dual Migraine Therapy for your VA Patients

1 Provider: Submit a Consult Request to Prosthetics Department
Provider: Submit a Consult Request to Prosthetics Department
2 Prosthetics: Fax PO to eNeura Customer Care
Prosthetics: Fax PO to eNeura Customer Care
3 eNeura Customer Care drop-ships the SAVI Dual directly to the patient
eNeura Customer Care drop-ships the SAVI Dual directly to the patient

Company information

Email: customercare@eneura.com

Fax: 877.264.1818

Phone: 833.499.9300, option 1

Aruene Corporation
101 W. Dickman St, Ste 900
Baltimore, MD 21230

UEI:  KPYXBLSSLCM5

Cage Code:  8YSK9

Ordering Information

SAVI Dual Migraine Therapy Activation

Item # 16140-0020-13-3
Three (3) months activation of SAVI Dual Migraine Therapy

Item # 16140-0020-13-12
Twelve (12) months activation of SAVI Dual Migraine Therapy

Treat migraine attacks + Prevent Future Attacks

SAVI Dual is the only FDA cleared central neuromodulation therapy for both acute and preventive treatment in patients 12 years and older.

Effective

In a study of people who treated with STMS (SAVI Dual), 46% reported a 50% reduction of migraine days at 12 weeks. In another study, more people using SAVI Dual experienced pain freedom and freedom from bothersome migraine symptoms at 2 hours versus placebo. These benefits were sustained through 48 hours.

Safe

The most commonly reported device related adverse events: lightheadedness (3.7%), tingling (3.2%) and tinnitus (3.2%), these typically resolve immediately after treatment.  There have been no serious adverse events reported.

SAVI Dual is contraindicated for patients with conductive metal implants in the head and neck, excluding dental work. MRI Protocols may be a reasonable guide in assessing the safety of SAVI Dual in patients with metal in the head and neck.